Effect on Body Weight and Adipose Tissue by Cariprazine: A Head-to-Head Comparison Study to Olanzapine and Aripiprazole in Rats
Open Access
- 28 October 2020
- journal article
- research article
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 88 (4), 50
- https://doi.org/10.3390/scipharm88040050
Abstract
Cariprazine (Car) is a recently approved second generation antipsychotic (SGA) with unique pharmacodynamic profile, being a partial agonist at both dopamine D2/3 receptor subtypes, with almost 10 times greater affinity towards D3. SGAs are known to increase body weight, alter serum lipids, and stimulate adipogenesis but so far, limited information about the adverse effects is available with this drug. In order to study this new SGA with such a unique mechanism of action, we compared Car to substances that are considered references and are well characterized: olanzapine (Ola) and aripiprazole (Ari). We studied the effects on body weight and also assessed the adipogenesis in rats. The drugs were self-administered in two different doses to female, adult, Wistar rats for six weeks. Weekly body weight change, vacuole size of adipocytes, Sterol Regulatory Element Binding Protein-1 (SREBP-1) and Uncoupling Protein-1 (UCP-1) expression were measured from the visceral adipose tissue (AT). The adipocyte’s vacuole size, and UCP-1 expression were increased while body weight gain was diminished by Car. by increasing UCP-1 might stimulate the thermogenesis, that could potentially explain the weight gain lowering effect through enhanced lipolysis.Keywords
This publication has 54 references indexed in Scilit:
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical reviewTherapeutics and Clinical Risk Management, 2017
- An update of safety of clinically used atypical antipsychoticsExpert Opinion on Drug Safety, 2016
- Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive MoleculesInternational Journal of Molecular Sciences, 2016
- The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents outInternational Journal of Clinical Practice, 2015
- Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid AssociationJournal of Clinical Lipidology, 2013
- Weight Gain, Obesity, and Psychotropic PrescribingJournal of Obesity, 2011
- Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug designPharmacology & Therapeutics, 2010
- The Role of Thermogenesis in Antipsychotic Drug‐induced Weight GainObesity, 2009
- Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profilesMolecular Psychiatry, 2007
- Atypical antipsychotics and weightgain — a systematic reviewActa Psychiatrica Scandinavica, 2000